Singapore's Temasek injects investment in genomics business
Together with Yun Feng, it co-led a $75m round of funding.
A report from Bloomberg said Singapore’s state-owned investment firm Temasek Holdings Pte made new investments in contract genomics organisation WuXi NextCODE, which is expanding in China as the country pushes into the emerging field of precision medicine.
Yunfeng Capital and Temasek co-led a $75m Series B round of financing into the company, WuXi NextCODE said in a statement. Other investors included Amgen Ventures, a fund founded by Amgen Inc., and private-equity firm 3W Partners.
Read the rest of the story here.